(Total Views: 655)
Posted On: 06/05/2022 9:24:32 AM
Post# of 154115
Excerpt: " We report on a pooled analysis of n = 28 mTNBC patients (pts) showing that leronlimab has potent antitumor activity with improved 1 year progression free (PFS) & overall survival (OS) with few treatment emergent adverse events (TEAEs).
Discuss
Discuss
(2)
(0)
